Account

Sign in to access your account and subscription

IP News

Highlights of the latest intellectual property news and cases from around the country.

9 minute read May 01, 2004 at 02:10 PM
By
Kathlyn Card-Beckles
IP News

Patent Term Extension Denied for Combination Drug

In The Arnold Partnership v. Dudas, 2004 WL 574480, CV-03-1339 (Fed. Cir. March 24, 2004), the Federal Circuit affirmed the district court's denial of a term extension for the drug marketed under the name Vicoprofen.

This premium content is locked for The Intellectual Property Strategist subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.

October 01, 2026